Your Client Rank:
Loading...
99
Updated 02-Jun-2025
| Company | Sales | Gross M. | SGA % Sales | R&D % Sales | Trading M. | Tax Rate | Net Income | EPS |
| | | | | | | | |
| Ascendis | 48.9% | -0.7% | -23.7% | -29.0% | | | | |
| Lilly | 18.2% | 0.3% | -5.5% | -11.0% | 10.1% | -0.5% | 31.1% | 31.3% |
| Novo | 12.3% | -0.2% | -2.0% | -2.6% | 1.6% | 1.0% | 14.3% | 15.4% |
| Vertex | 10.6% | 0.8% | -1.3% | -18.6% | 52.5% | -26.0% | >100% | >100% |
| Daiichi | 9.4% | 1.5% | 2.2% | -4.2% | 4.3% | 3.9% | 12.3% | 13.0% |
| Eisai | 7.0% | -1.7% | -3.3% | -5.9% | 12.0% | 1.6% | 17.4% | 18.7% |
| AbbVie | 6.5% | 0.1% | -3.8% | -6.6% | 4.4% | -1.5% | 12.8% | 12.7% |
| Sanofi | 6.3% | 0.9% | -3.3% | -2.7% | 4.9% | 0.5% | 10.0% | 10.6% |
| Astra | 5.1% | 0.4% | -0.9% | 0.0% | 4.9% | 0.8% | 9.4% | 9.5% |
| Regeneron | 5.1% | 0.2% | -1.6% | -0.2% | 1.1% | 8.4% | 5.2% | 5.9% |
| Chugai | 5.0% | 1.3% | -2.5% | -1.0% | 3.1% | -1.4% | 9.7% | 9.3% |
| JNJ | 4.1% | -0.4% | -1.4% | -4.1% | 2.5% | 0.5% | 5.4% | 6.2% |
| Roche | 4.1% | 0.1% | -1.4% | -1.2% | 1.4% | 2.3% | 6.1% | 5.6% |
| Novartis | 3.4% | 0.1% | -1.3% | 0.3% | 1.6% | 0.6% | 5.2% | 6.4% |
| Teva | 3.3% | 1.5% | -6.0% | 0.1% | 3.5% | 2.6% | 9.5% | 8.3% |
| Gilead | 3.2% | -0.2% | -2.4% | -11.6% | 9.7% | -6.2% | 17.1% | 17.0% |
| Amgen | 3.1% | -0.1% | -1.2% | 2.4% | -1.0% | 1.6% | 3.8% | 4.0% |
| Merck | 2.6% | -0.1% | -0.9% | -4.5% | 2.3% | 0.0% | 5.7% | 6.7% |
| Shionogi | 2.4% | -0.8% | 0.8% | -0.7% | -2.1% | 4.8% | -0.2% | 0.7% |
| Glaxo | 1.9% | -0.2% | 0.8% | 1.5% | 1.4% | 0.3% | 4.3% | 3.7% |
| Bayer | 1.4% | 1.6% | -2.2% | -1.3% | 16.1% | | 3.7% | 3.8% |
| Takeda | 1.3% | 0.4% | -0.7% | 1.1% | 15.3% | -9.6% | 3.2% | 4.5% |
| Lundbeck | 1.2% | 0.2% | -0.9% | 4.3% | 3.3% | 9.8% | -0.5% | -3.0% |
| Biogen | -0.7% | 0.5% | -0.3% | 0.2% | 0.9% | 2.4% | 0.7% | 1.0% |
| Pfizer | -3.5% | 0.0% | -0.2% | 2.7% | -1.5% | 1.1% | -4.5% | -4.5% |
| Astellas | -3.8% | -1.0% | -3.8% | 2.6% | 1.1% | -7.0% | -2.8% | -1.8% |
| Bristol | -5.1% | 0.4% | 1.2% | -13.6% | 28.0% | -20.5% | 36.6% | 37.2% |
| Neurocrine | | | | | | | | |
| EU Major | 5.0% | 0.5% | -1.8% | -0.9% | 3.8% | 0.6% | 8.2% | 7.6% |
| Other EU | 11.8% | 0.3% | -7.6% | -5.6% | 45.9% | -23.1% | >100% | |
| US Major | 4.4% | 0.2% | -2.2% | -7.0% | 6.1% | -2.0% | 11.4% | 17.6% |
| US Big Biotech | 4.1% | 0.2% | -2.1% | -6.5% | 5.6% | -2.4% | 12.1% | 10.5% |
| Other US | 3.3% | 1.5% | -6.0% | 0.1% | 3.5% | 2.6% | 9.5% | 8.3% |
| Japanese | 3.0% | 0.4% | -0.7% | -0.7% | 6.0% | -1.5% | 5.6% | 7.3% |
